Synthesis of Entecavir and Its Novel Class of Analogs

Authors:

Abstract
Due to the slow kinetics of viral clearance and the spontaneous genetic variability of hepatitis B virus (HBV), antiviral therapy of chronic hepatitis B remains a clinical challenge. Entecavir (S.10; a 2′‐deoxy carbocyclic guanosine analog with an exo‐cyclic double bond on the 5′‐position; Fig. 14.7.1) has been approved in the U.S. for the therapy of chronic hepatitis B. Entecavir is synthesized from D‐ribose via a key allylic alcohol (S.3) intermediate. This intermediate is also utilized to synthesize entecavir‐modified carbocyclic nucleosides S.13, S.15, S.19, and S.22. Curr. Protoc. Nucleic Acid Chem. 47:14.7.1‐14.7.17. © 2011 by John Wiley & Sons, Inc.

This publication has 25 references indexed in Scilit: